Nishida Miwa
Dept. of Regulatory and Clinical Development, Roche Diagnostics K. K.
Gan To Kagaku Ryoho. 2014 Dec;41(13):2529-34.
The personalized health care, it is defined as a medical care which provide the optimal therapy for each individual in consideration of a patient's individual difference, such as a genetic background and a physiological state. A companion diagnosis to stratify a patient appropriately is essential for the spread of personalized health care, and it is important that a companion diagnostic reagent used for the companion diagnosis is properly developed and clinically applied. However, as for the development of companion diagnostics and pharmaceuticals that require it, there are still many challenges such as its business model of cooperation of diagnostics companies and pharmaceutical companies, also, the regulations related to companion diagnostics. Furthermore, even in clinical practice, there are many issues such as the way of reimbursement for companion diagnostics and also the handling of laboratory developed test (LDT) as companion diagnostics. These are issues that should continue to discuss with industry, government and academia. In this report, from the point of view of a diagnostics company, we discuss the various challenges in clinical applications from the development of companion diagnostics.
个性化医疗是指考虑患者个体差异(如基因背景和生理状态)为每个个体提供最佳治疗的医疗服务。对患者进行适当分层的伴随诊断对于个性化医疗的推广至关重要,并且用于伴随诊断的伴随诊断试剂的正确开发和临床应用也很重要。然而,对于伴随诊断及其所需药物的开发,仍存在许多挑战,例如诊断公司与制药公司的合作商业模式,以及与伴随诊断相关的法规。此外,即使在临床实践中,也存在许多问题,如伴随诊断的报销方式以及将实验室开发的检测(LDT)作为伴随诊断的处理方式。这些都是应继续与行业、政府和学术界讨论的问题。在本报告中,我们从诊断公司的角度,探讨伴随诊断开发在临床应用中的各种挑战。